Antibody production: End-to-end workflow solutions for mAbs and more

Let’s make your molecule a medicine

Breakthrough cancer treatments, autoimmune disease control, infectious disease management, and more.

Antibody therapeutics are unlocking new clinical possibilities, and the pressure to get them to market quickly has never been higher.

Whether you're optimizing your mAb process, developing a novel protein therapeutic, or preparing for commercial scale-up, we can help you move forward—quickly and confidently.

Move your mAb or mAb variant to market with speed and precision

Backed by decades of experience with protein therapeutics, deep scientific expertise, and proven technologies, we’ll work alongside you to simplify complexity and avoid delays in your antibody journey.

Get collaborative support for mAb and other antibody-derived molecules—from research and process development through regulatory‑ready GMP production at scale.

Process development

Develop a robust, scalable process to get your therapeutic antibody to clinic without compromising quality or wasting time.

Process intensification

Optimize upstream and downstream steps to boost productivity, reduce costs, and maximize efficiency across your entire workflow.

Bioprocessing from cell line
to finish line

Upstream: Develop and expand your cells

Start strong with robust cell line development, consistent protein expression, and media and feeding strategies that drive quality and productivity.

Downstream: Purify with efficiency and precision

From capture to polishing, streamline complex protein separation and purification sequences so you can recover more product with fewer surprises.

Manufacturing next-generation protein therapeutics

Standard mAb processes might not work for some antibody-derived molecules, and missteps can be costly. Together, we can navigate the unique manufacturing hurdles that can come with novel protein formulations.

Antibody fragments (Fabs)

Purify diverse fragments with resins that allow for high flow rates and high productivity suitable for large-scale manufacturing.

Learn more

Bispecific antibodies (bsAbs)

Explore chromatography solutions to take on variable binding affinities and a high impurity concentrations.

Learn more

Antibody-drug conjugates (ADCs)

Review our extensive extractables and leachables (E&L) data or develop a custom study to safeguard your ADC with a regulatory-ready process.

Learn more

High-concentration antibodies

Access strategies to address aggregation, filter fouling, and shear stress associated with high-viscosity subcutaneous formulations.

Learn more

Discover how chromatography supports mAb variant purification

This video highlights practical chromatography strategies for purifying bispecifics, fragments, and other mAb variants—focusing on capture and polishing approaches that help enable robust, scalable downstream processes.

Protein A and Protein L affinity resins for effective capture across antibody formats
Ion exchange chromatography using Capto™ resins for polishing and impurity removal
Hydrophobic interaction and multimodal chromatography for complex, hard‑to‑separate variants

Learn more about antibody production

Controlling mAb aggregates in chromatography process development

Learn about downstream chromatographic strategies that successfully remove aggregates.

Purification’s critical role in antibody manufacturing

Explore thoughtful resin selection and modern scale-up strategies.

Explore scale-up and support options

Maintain momentum as you grow

Streamline your capacity expansion projects with flexible platform options, a suite of services, and hands-on support.

Learn and train with our team

Get the most out of your production processes and upskill your staff with global courses taught by industry experts.

Let’s build your process together

We can help you develop an efficient, scalable process so you can reach key milestones without wasting time.

Frequently asked questions about mAb manufacturing

What are the essential steps in a mAb workflow?

A mAb workflow begins with cell line development and moves to upstream expansion, harvest clarification, protein purification, and final formulation. Each stage shapes yield, quality, and cost. We help you link these steps with scalable bioprocessing tools that keep your workflow predictable.

Why is strong cell line development critical for mAb success?

Cell line development creates the cell system that expresses your antibody. A strong cell line improves stability, yield, and quality. Our upstream tools support high‑titer cell culture and consistent performance as you can scale up.

How do I choose the right chromatography approach for my mAb?

Most traditional mAb workflows begin with a Protein A capture step. This is followed by polishing steps, commonly using ion exchange chromatography or multimodal or hydrophobic interaction chromatography for challenging separation and to refine purity. In research applications, the capture step is commonly followed by a SEC step.

Your molecule’s behavior and impurity profile will guide the resin choices, and novel protein therapeutics such as ADCs, bispecifics, or fragments will have unique structural elements that might call for a different approach. We offer diverse resins and columns that help simplify protein separation decisions at every scale for any antibody molecule.

How should I evaluate clarification methods for high‑cell‑density harvests?

Harvest clarification removes cells and debris before purification. Depth filtration works well with dense feeds. Centrifugation or tangential flow filtration (TFF) suit other formats. We can help you choose a protein purification method that protects your throughput and downstream consistency.

Where does viral clearance fit in an end‑to‑end mAb process?

Viral clearance uses low‑pH inactivation, filtration, and orthogonal steps to protect product quality and patients. These steps sit after capture and before final formulation. It strengthens the reliability of your downstream sequence.

Our filtration and ultrafiltration and diafiltration (UF/DF) solutions help you meet safety targets without compromising efficiency.

How do I know when my mAb process is ready for scale‑up?

You’re ready for scale‑up when upstream growth, critical quality attributes (CQAs), and recovery remain stable across runs. Predictable behavior in both upstream and downstream bioprocessing is a strong indicator. We help teams assess readiness and build scalable workflows that reduce operational risk.

How can bioprocess modelling support decisions across the mAb workflow?

Bioprocess modelling helps predict how cell line development, chromatography, or protein purification changes will affect yield and robustness. This capability reduces trial‑and‑error and surfaces risks earlier. We provide scalable systems and data that integrate cleanly into bioprocessing models.

What signals that my process is robust enough for GMP manufacturing?

A GMP‑ready process delivers consistent batches and stable CQAs. Defined operating limits and repeatable purification behavior support this stability. We help map gaps and strengthen your workflow, so you’re prepared for regulatory and operational scrutiny.

Shop in your local currency and language

Antibodies in action: Optimize your workflow, fast

From upstream to downstream, get the equipment, consumables, and expertise you need to build a robust mAb or novel protein therapeutic workflow.

Let’s make your molecule a medicine